Large companies have been stepping up deal activity in the epigenetics space over the last three years. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has disclosed the most deals covering the broadest range of epigenetic targets, including histone methyltransferases, BET family proteins and HDACs. But last week's deal between Constellation Pharmaceuticals Inc. and Genentech Inc., a unit of Roche (SIX:ROG; OTCQX:RHHBY), has the largest disclosed upfront payment and includes a "broad" number of undisclosed targets. In the precompetitive space, the non-profit Structural Genomics Consortium is leading an epigenetics research effort that includes Eli Lilly and Co. (NYSE:LLY), GSK, Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN). At least three companies with programs against novel epigenetic targets have not yet announced partnerships. Source: BCIQ: BioCentury Online Intelligence

Selected partnerships

Deal focus

Financial terms

Date